Integra LifeSciences
Holdings Corporation IART today announced that the Food and Drug
Administration (FDA) has approved an expanded indication for use of the
Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior
lumbar interbody fusion (ALIF) procedures. The new stand-alone indication
includes four points of fixation, which is composed of two screws and a
SpinPlate™. The Integra® Vu aPOD™ Prime IBD will be featured at the Congress
of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in
Chicago, Illinois.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in